If your 12-week marker shows solid progress, the data supports confidence that the second half of the protocol will continue delivering results
After 24 weeks treatment, there were no significant differences between the groups for the primary endpoint of change in left ventricular ejection fraction, regardless of whether the patients had comorbid diabetes or not
This is a research-supplier comparison, not a treatment guide
Food and Drug Administration (FDA) is investigating the association of GLP-1 receptor agonists, such as Ozempic and Mounjaro, with side effects including suicidal thoughts, hair loss, and airway obstructions
Additionally, growing hospital-based clinical research and collaborations with pharmaceutical companies enhance early drug access and drive higher adoption rates